Home Tags Sanofi
Under the new agreement, Paris-based Sanofi would gain sole global rights to Kevzara and sole ex-U.S. rights to Praluent, while Tarrytown’s Regeneron would gain sole U.S. rights to Praluent.
According to the lawsuit, “Zantac’s unprecedented sales were possible only because of a deception perpetrated by the drug’s manufacturers on consumers.”
Judge Richard Andrews’ Aug. 28 ruling overturned portions of a jury verdict in February that found Amgen’s patents on its cholesterol drug Repatha were valid. Regeneron and Sanofi sell rival drug Praluent.
In the U.S., it is indicated for use by prescription to treat moderate-to-severe atopic dermatitis, also known as eczema.
The drug is the first FDA-approved treatment for patients with advanced forms of a skin cancer known as cutaneous squamous cell carcinoma.
These cancers commonly appear on sun-exposed areas of the body such as the face, ears, neck, lips and backs of the hands.
The European agency will also review the marketing authorization application for cemiplimab, which is used to treat patients with metastatic cutaneous squamous cell carcinoma.
The antibody drug was approved for use in the U,S. last March.
The companies will increase their investments in the development of cancer drug cemiplimab and food allergy drug dupilumab.
Dupilumab showed positive results in adults with eosinophilic esophagitis, an allergic inflammatory disease that damages the esophagus.
The antibody drug will be marketed as Dupixent and available to adults with moderate to severe atopic dermatitis .
The European Commission approved the use of Kevzara under certain conditions to treat adults with moderately to severely active rheumatoid arthritis.
The new human antibody drug will be used to treat a chronic inflammatory disease that affects about 1.3 million Americans.
Dupixent will go on the U.S. market this week as the first antibody medicine for uncontrolled itching and rashes in adults with atopic dermatitis.
Under the proposed swap, Boehringer will acquire Sanofi’s animal care subsidiary, while Sanofi will obtain Boehringer’s consumer health care business unit.
12Page 1 of 2